CN101175747B - 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物 - Google Patents

作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物 Download PDF

Info

Publication number
CN101175747B
CN101175747B CN2006800165544A CN200680016554A CN101175747B CN 101175747 B CN101175747 B CN 101175747B CN 2006800165544 A CN2006800165544 A CN 2006800165544A CN 200680016554 A CN200680016554 A CN 200680016554A CN 101175747 B CN101175747 B CN 101175747B
Authority
CN
China
Prior art keywords
compound
methyl
salt
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800165544A
Other languages
English (en)
Chinese (zh)
Other versions
CN101175747A (zh
Inventor
K·加瓦迪纳斯
P·K·亚达夫
D·R·斯塔克
I·R·克莱门斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101175747A publication Critical patent/CN101175747A/zh
Application granted granted Critical
Publication of CN101175747B publication Critical patent/CN101175747B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800165544A 2005-05-13 2006-05-10 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物 Expired - Fee Related CN101175747B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68091105P 2005-05-13 2005-05-13
US60/680,911 2005-05-13
PCT/US2006/018061 WO2006124447A2 (en) 2005-05-13 2006-05-10 Substituted n-arylpyrrolidines as selective androgen receptor modulators

Publications (2)

Publication Number Publication Date
CN101175747A CN101175747A (zh) 2008-05-07
CN101175747B true CN101175747B (zh) 2011-06-22

Family

ID=37057376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800165544A Expired - Fee Related CN101175747B (zh) 2005-05-13 2006-05-10 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物

Country Status (17)

Country Link
US (1) US7807691B2 (enExample)
EP (1) EP1891038B1 (enExample)
JP (1) JP5089578B2 (enExample)
CN (1) CN101175747B (enExample)
AT (1) ATE412647T1 (enExample)
AU (1) AU2006247738A1 (enExample)
BR (1) BRPI0610183A2 (enExample)
CA (1) CA2608419A1 (enExample)
CY (1) CY1108690T1 (enExample)
DE (1) DE602006003432D1 (enExample)
DK (1) DK1891038T3 (enExample)
ES (1) ES2314922T3 (enExample)
MX (1) MX2007014053A (enExample)
PL (1) PL1891038T3 (enExample)
PT (1) PT1891038E (enExample)
SI (1) SI1891038T1 (enExample)
WO (1) WO2006124447A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015567A1 (ja) * 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
US8013008B2 (en) 2006-11-30 2011-09-06 Takeda Pharmaceutical Company Limited Cyclic amine compound
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR067823A1 (es) 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009133861A1 (ja) * 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
GEP20156285B (en) * 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗ウイルス性アザ糖を含有するヌクレオシド
SMT202300072T1 (it) 2014-03-28 2023-05-12 Univ Duke Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
ES2945834T3 (es) 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
MA54946A (fr) 2019-02-12 2021-12-22 Radius Pharmaceuticals Inc Procédés et composés
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN114746400A (zh) * 2019-11-20 2022-07-12 南京明德新药研发有限公司 用作选择性雄激素受体调节剂的化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2025160286A1 (en) * 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688527A (zh) * 2002-08-12 2005-10-26 武田药品工业株式会社 稠合的苯衍生物以及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
US7495016B2 (en) * 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
US20060148893A1 (en) * 2003-06-10 2006-07-06 Blanc Jean-Baptiste E Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688527A (zh) * 2002-08-12 2005-10-26 武田药品工业株式会社 稠合的苯衍生物以及用途

Also Published As

Publication number Publication date
WO2006124447A2 (en) 2006-11-23
DK1891038T3 (da) 2009-01-19
CN101175747A (zh) 2008-05-07
EP1891038A2 (en) 2008-02-27
SI1891038T1 (sl) 2009-04-30
PL1891038T3 (pl) 2009-04-30
CY1108690T1 (el) 2014-04-09
JP2008540554A (ja) 2008-11-20
CA2608419A1 (en) 2006-11-23
MX2007014053A (es) 2008-02-05
EP1891038B1 (en) 2008-10-29
DE602006003432D1 (de) 2008-12-11
BRPI0610183A2 (pt) 2012-12-04
AU2006247738A1 (en) 2006-11-23
US7807691B2 (en) 2010-10-05
WO2006124447A3 (en) 2007-03-29
JP5089578B2 (ja) 2012-12-05
ATE412647T1 (de) 2008-11-15
PT1891038E (pt) 2008-12-02
ES2314922T3 (es) 2009-03-16
US20080176864A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CN101175747B (zh) 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物
JP5204650B2 (ja) アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
CN102026974B (zh) 四氢环戊二烯并[b]吲哚雄激素受体调节剂
CN113382990A (zh) 取代的吡咯烷酰胺iii
TW200951114A (en) Phenyl or pyridinyl substituted indazoles derivatives
TW200836746A (en) Alpha2C adrenoreceptor agonists
JP7214053B2 (ja) 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物
TW202017916A (zh) 新穎緩激肽ｂ２受體拮抗劑及其用途
CN113727973B (zh) 可用作类法尼醇x受体调节剂的取代酰胺化合物
CN113874367B (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
TW201022234A (en) Pyrrolidines
TW202525792A (zh) 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物
WO2025051180A1 (zh) 内酰胺类衍生物及其应用
CN105451737A (zh) 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法
AU2009238444B2 (en) 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
AU2009238445B2 (en) 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
CN119790048A (zh) 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
WO2025160220A2 (en) Tead inhibitors and methods of use
CN119930582A (zh) 稠环类cbl-b抑制剂
CN118973564A (zh) 作为trpa1抑制剂的哒嗪酮化合物
HK40064838B (zh) 吲唑类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110622

Termination date: 20120510